Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandra Bhagat PharmaBOM:542934 +3.55%65 PEG Ratio is 0.88 as of Jul. 30, 2026, which is 1% below its 10-year median of 0.89. GuruFocus rates BOM:542934 with a GF Score™ of 65/100 and a GF Value™ of ₹70.17 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 49 Medical Distribution companies, Chandra Bhagat Pharma ranks better than 69.39% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Chandra Bhagat Pharma's PEG Ratio or its related term are showing as below:
BOM:542934'
s PEG Ratio Range Over the Past 10 Years
Min: 0.81 Med: 0.89 Max: 1.12
Current: 0.88
During the past 10 years, Chandra Bhagat Pharma's highest PEG Ratio was 1.12. The lowest was 0.81. And the median was 0.89.
BOM:542934's PEG Ratio is ranked better than 69.39% of 49
companies
in the Medical Distribution industry
Industry Median: 1.94
vs BOM:542934: 0.88
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Chandra Bhagat Pharma (BOM:542934) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Chandra Bhagat Pharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma PEG Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Chandra Bhagat Pharma (BOM:542934) has a PEG Ratio of 0.88 as of Jul. 30, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Chandra Bhagat Pharma and its competitors. This is near median its historical median of 0.89. Over the past decade, Chandra Bhagat Pharma's PEG Ratio has ranged from 0.81 to 1.12. According to the industry distribution chart, Chandra Bhagat Pharma ranks #15 out of 49 companies in the Medical Distribution industry, placing it in the top 30.6%.
Is Chandra Bhagat Pharma's PEG Ratio too high?
Chandra Bhagat Pharma's current PEG Ratio of 0.88 is near median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 1.12. The Medical Distribution industry median PEG Ratio is 1.94. Chandra Bhagat Pharma's value of 0.88 is 54.6% below this industry median. Based on the distribution chart, Chandra Bhagat Pharma ranks #15 out of 49 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Chandra Bhagat Pharma has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's PEG Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #15 out of 49 companies for PEG Ratio. This puts Chandra Bhagat Pharma in the upper half of its industry. The industry median PEG Ratio is 1.94. Chandra Bhagat Pharma's value of 0.88 is 54.6% below this benchmark. Historically, Chandra Bhagat Pharma's own PEG Ratio has ranged from 0.81 to 1.12 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 1.94, Chandra Bhagat Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Distribution company?
The median PEG Ratio among Medical Distribution companies is 1.94, based on 49 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandra Bhagat Pharma's current PEG Ratio of 0.88 is 54.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median PEG Ratio is 1.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current PEG Ratio is 0.88, which is near median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Possible Value Trap. The stock's GF Value™ is ₹70.17, compared to a current price of ₹34.40 — trading 51% below its estimated fair value. The current PEG Ratio is 0.88, which is near median its 10-year median of 0.89 and 54.6% below the Medical Distribution industry median of 1.94. Chandra Bhagat Pharma's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current PEG Ratio is 0.88 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹34.40 is trading 51% below its estimated GF Value™ of ₹70.17.
GuruFocus considers Chandra Bhagat Pharma to be Possible Value Trap.
Key valuation signals for BOM:542934:
PEG Ratio: 0.88 (near median its 10-year median of 0.89)
GF Value™: ₹70.17 vs. price of ₹34.40 (51% below fair value)
Industry Position: 54.6% below the Medical Distribution median (#15 of 49)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
65GF Score
Get the complete analysis for BOM:542934
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
